Developments for TILs and TCR modified cell therapy in solid tumors [Video]

Sebastian Klobuch, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses advances in tumor-infiltrating lymphocytes (TILs) and T cell receptor (TCR) modified cell therapy in oncology. Findings from a Phase III trial (NCT02278887) that compared TILs against checkpoint inhibitors in melanoma demonstrated the superiority of TILs in terms of progression-free survival (PFS), which is further exemplified by the recent approval of lifileucel in melanoma. Additional advances in TCR modified cell therapies include targeting MAGE-A4 in sarcoma. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.